Yttrium 90 microspheres for the treatment of hepatocellular carcinoma

Recent Results in Cancer Research

Volumn 190, Issue , 2013, Pages 207-224

  Memon, Khairuddin ^a   Lewandowski, Robert J ^a   Riaz, Ahsun ^a   Salem, Riad ^a,b,c  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Interventional Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MACROSALB TC 99M; MICROSPHERE; PROTON PUMP INHIBITOR; YTTRIUM 90;

ARTICLE; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; BLOOD VESSEL INJURY; CANCER SURVIVAL; DIGESTIVE SYSTEM ULCER; DOSIMETRY; DRUG DELIVERY SYSTEM; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; LIVER ANGIOGRAPHY; LIVER BLOOD VESSEL; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER TRANSPLANTATION; LUNG SHUNTING; NAUSEA; PAIN; PARTICLE SIZE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); POSTRADIOEMBOLIZATION SYNDROME; PRIORITY JOURNAL; RADIATION PNEUMONIA; RADIATION SICKNESS; RADIOEMBOLIZATION; RADIOGRAPHY; SIDE EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING;

CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER; LIVER NEOPLASMS; MICROSPHERES; PATIENT SELECTION; RADIOPHARMACEUTICALS; TUMOR MARKERS, BIOLOGICAL; YTTRIUM RADIOISOTOPES;

EID: 84868313408     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-16037-0_14     Document Type: Article

References (63)

1. El-Serag HB (2002) Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36(5 Suppl 1):S74-S83 (Pubitemid 35253466)
2. Alterkruse SFMK, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival benefits in the United States from 1975 to 2005. J Clin Oncol 27:1485-1491
3. Parkin DMBF, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
4. Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5 Suppl 1):S5-S16 (Pubitemid 39423365)
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25-34
7. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB 3rd, Mulcahy MF (2011) Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology 140(2):497-507. doi:10.1053/j.gastro.2010.10.049 e492 DOI S0016-5085(10)01587-8[pii]
8. Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G (2004) Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10(3):449-455 (Pubitemid 38380323)
9. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A 3rd, Nemcek AA Jr, Gates VL, Abecassis M, Omary RA, Salem R (2007) Safety and efficacy of (90)Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47(1):71-81
10. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1):52-64
11. Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Omary RA, Benson AB 3rd, Salem R (2010) Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 255(3):955-965. doi:10.1148/radiol.10091473 DOI 255/3/955[pii]
12. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9(8):1920-1928
13. Riaz A, Miller FH, Kulik LM et al (2010) Imaging response in the primary index lesion and clinical outcomes following transarteial locoregional theapy for hepatocellular carcinoma. JAMA 303(11):1062-1069
14. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734-1739 (Pubitemid 34607087)
15. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164-1171 (Pubitemid 34454013)
16. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693-699 (Pubitemid 26079803)
17. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montana X, Llovet JM, Bruix J (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3):474-481 (Pubitemid 46201723)
18. Markowitz J (1952) The hepatic artery. Surg Gynecol Obstet 95(5):644-646
19. Vente MA, Zonnenberg BA, Nijsen JF (2010) Microspheres for radioembolization of liver malignancies. Expert Rev Med Devices 7(5):581-583. doi:10.1586/erd.10.48
20. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF (2010) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. doi:10.1053/j.gastro.2010.10.049 DOI S0016-5085(10)01587- 8[pii]
21. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF (2002) Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 13(9 Pt 2):S223-S229
22. Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251-1278 (Pubitemid 44259009)
23. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA (1965) Radiation Hepatitis. Am J Roentgenol Radium Ther Nucl Med 93:200-208
24. Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M, Roberts CA, Goin JE (2004) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S194-S205 (Pubitemid 39423388)
25. Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30(5):969-977
26. Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z, Atassi B, Barrett K, Gowland P, Oman B, Lewandowski RJ, Gates VL, Thurston KG, Wong CY (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16(7):911-935 (Pubitemid 40993515)
27. Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA Jr, Kulik L, Geschwind JF, Murthy R, Rilling W, Liu D, Bester L, Bilbao JI, Kennedy AS, Omary RA, Salem R (2007) Radioembolization with (90)Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 30(4):571-592 (Pubitemid 350092259)
28. Salem R, Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Ibrahim S, Nemcek AA Jr, Omary RA, Madoff DC, Murthy R (2007) Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 10(1):12-29 (Pubitemid 350008084)
29. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10):698-711
30. Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT (2002) Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology 224(2):542-547 (Pubitemid 34809139)
31. Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, Ahrar K, Wallace MJ, Cohen A, Coldwell DM, Kennedy AS, Hicks ME (2005) Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25(Suppl 1):S41-S55 (Pubitemid 41686061)
32. Cosin O, Bilbao JI, Alvarez S, de Luis E, Alonso A, Martinez-Cuesta A (2007) Right gastric artery embolization prior to treatment with yttrium-90 microspheres. Cardiovasc Intervent Radiol 30(1):98-103 (Pubitemid 44900497)
33. Chen JH, Chai JW, Huang CL, Hung HC, Shen WC, Lee SK (1999) Proximal arterioportal shunting associated with hepatocellular carcinoma: features revealed by dynamic helical CT. Am J Roentgenol 172(2):403-407
34. Ho S, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ, Li AK (1996) Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 23(8):947-952 (Pubitemid 26278795)
35. Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ (2002) Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F] FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 29(6):815-820
36. Wong CY, Salem R, Qing F, Wong KT, Barker D, Gates V, Lewandowski R, Hill EA, Dworkin HJ, Nagle C (2004) Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 45(11):1892-1897 (Pubitemid 47618448)
37. WHO (1979) WHO handbook for reporting results of cancer treatment. WHO offset publication, Geneva, Switzerland, WHO No. 48
38. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
39. Forner A, Ayuso C, Hessheimer AJ, de Lope CR, Reig M, Bianchi L, Llovet JM, Bruix J (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115(3):616-623
40. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol 35(3):421-430 (Pubitemid 32844200)
41. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, Abecassis M, Baker T, Gates V, Nayar R, Miller FH, Sato KT, Omary RA, Salem R (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49(4):1185-1193
42. Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF, Baker T, Wang E, Gupta R, Nayar R, Benson AB, Abecassis M, Omary R, Salem R (2011) Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 54(4):695-704
43. Rhee TK, Naik NK, Deng J, Atassi B, Mulcahy MF, Kulik LM, Ryu RK, Miller FH, Larson AC, Salem R, Omary RA (2008) Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 19(8):1180-1186
44. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH, Newman S, Omary R, Abecassis M, Benson AB 3rd, Salem R (2009) Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 27(34):5734-5742
45. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, Hunter RD, Nemcek AA Jr, Abecassis MM, Haines KG 3rd, Salem R (2006) Yttrium-90 microspheres (THERASPHERE(R)) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94(7):572-586 (Pubitemid 44851918)
46. Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA 3rd, Kim HS (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21(2):224-230
47. Carr BI, Kondragunta V, Buch SC, Branch RA (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116(5):1305-1314
48. Ibrahim SM, Nikolaidis P, Miller FH, Lewandowski RJ, Ryu RK, Sato KT, Senthilnathan S, Riaz A, Kulik L, Mulcahy MF, Omary RA, Salem R (2009) Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 34(5):566-581
49. Saxena A, Bester L, Chua TC, Chu FC, Morris DL (2009) Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 49:453-459
50. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, Sergie Z, Wong CY, Thurston KG (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (therasphere): safety, tumor response, and survival. J Vasc Interv Radiol 16(12):1627-1639 (Pubitemid 44431160)
51. Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE Jr, Loehr SP, Overton C, Meranze S, Niedzwiecki J, Sailer S (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65(2):412-425
52. Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, Madoff DC, Gupta S, Wallace MJ, Ahrar K, Hicks ME (2005) Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 16(7):937-945 (Pubitemid 40993516)
53. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, Chopitea A, Inarrairaegui M, Arbizu J, Bilbao JI (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112(7):1538-1546 (Pubitemid 351441166)
54. Young JY, Rhee TK, Atassi B, Gates VL, Kulik L, Mulcahy MF, Larson AC, Ryu RK, Sato KT, Lewandowski RJ, Omary RA, Salem R (2007) Radiation dose limits and liver toxicities resulting from multiple Yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 18(11):1375-1382 (Pubitemid 47628904)
55. Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, Miller F, Ryu RK, Ibrahim S, Sato KT, Kulik LM, Mulcahy MF, Omary R, Murthy R, Reiser MF, Salem R (2008) Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci 53(9):2556-2563
56. Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, Ryu RK, Sato KT, Gates V, Abecassis MM, Omary RA, Baker TB, Salem R (2009) Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 16(6):1587-1596
57. Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, Miller F, Ryu RK, Ibrahim S, Sato KT, Kulik LM, Mulcahy MF, Omary R, Murthy R, Reiser MF, Salem R (2008) Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with (90)yttrium microspheres. Dig Dis Sci 53(9):2556-2563
58. Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Ibrahim S, Mulcahy MF, Kulik L, Liu DM, Riaz A, Omary RA, Kennedy AS (2008) Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 31(5):431-438
59. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, Metreweli C, Johnson PJ, Li AK (1995) Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33(4):919-924
60. TheraSphere (2004) TheraSphere Yttrium-90 microspheres package insert, MDS Nordion, Kanata, Canada
61. Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, Nunez R, Habbu A, Liu D, Ross W, Cohen AM, Censullo M (2007) Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 18(4):553-561 quiz 562 (Pubitemid 46566540)
62. Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I, De la Riva S, Sola J, Bilbao JI, de Luis E, Sangro B (2007) Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol 102(6):1216-1220 (Pubitemid 46802020)
63. Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, Hicks ME (2007) Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol 18(12):1588-1591 (Pubitemid 350151878)